Global Liver Institute
Liver Health Policy
GLOBAL LIVER INSTITUTE
Policy Agenda
GLI advocates for the elevation of liver health to its rightful place on the global public health agenda commensurate with its prevalence and impact.
GLI engages with
U.S. Federal Agencies: CMS, CDC, NIH, NIDDK, VA, & more
U.S. Congress
Global Health Agencies: WHO, EMA, & more
Priority Initiatives
Obesity and Liver Health
Obesity and Liver Health: Promote adequate, equitable access to treatment for upstream risk factors for fatty liver disease/metabolic dysfunction-associated steatotic liver disease, which include obesity and other metabolic conditions
Health Disparities
Health Disparities: Address inequities in the care of people impacted by liver disease
Liver Health Policy
Liver Health Policy: Advance Liver Health is Public Health globally, the U.S. NASH Action Plan, and policies that prevent and address the more than 100 types of liver diseases and related conditions
Liver Health Regulations
Liver Health Regulations: Work with regulators to better incorporate the experiences, perspectives, and needs of liver patients into regulatory decision-making
Engaged Initiatives
Liver Health Research
Liver Health Research: Advocate for funding that ensures meaningful growth of vital liver health research and public health programs
Transplant
Transplant: Urgently respond to the inequities that impact organ transplantation; improve care for transplant patients, and increase the number of available organs
Viral Hepatitis
Viral Hepatitis: Increase support for hepatitis programs and raise awareness of viral hepatitis; advocate for the elimination of viral hepatitis
Value
Value: Advance healthcare policies that reflect the unique ability patients have to contribute to the understanding of their condition and treatment management
Patient Access and Reimbursement
Patient Access and Reimbursement: Support policy solutions that curb patients’ health care expenses, and protect access to transformative therapies
Key Policies
Access to Telehealth
Policy Highlights
Leading multiple Virtual Liver Advocacy Days and Congressional Briefings that educate policy makers about liver health
Testifying before the U.S. Congress to reform the Organ Procurement and Transplantation Network, which led to the passage of the Securing the U.S. Organ Procurement and Transplantation Network Act to modernize and add transparency to the system
Working with the U.S. Congress to advance patient-centric legislative packages and introduce liver-specific bills like the LIVER Act and the NASH Care Act
GLI Founder, Donna R. Cryer, JD joins federal and patient advocacy leaders while President Biden signs the Securing the U.S. Organ Procurement and Transplantation Network Act, 2023
Global Policy
Liver Health Advocacy with the European Parliament
In October 2023, LHPH Director Giacomo Donnini represented GLI at a policy event in partnership with the European Liver Patients Association (ELPA) at the European Union Parliament. The event brought together experts, policymakers, patient advocates, and other stakeholders active in the field of liver cancer to explore what can be done to ensure that no patient in Europe is left behind. As part of efforts to raise consciousness of liver health among Members of the European Parliament, he emphasized the importance of cooperation between all the different actors in the field as a united voice is the only way to convey a strong message to the politicians.
Externally-Led Patient-Focused Drug Development Meetings
Externally-Led Patient-Focused Drug Development (EL-PFDD) Meetings are held to systematically obtain the patient perspective on specific decisions and their treatments to provide context for regulatory decisions for new drugs. GLI holds EL-PFDD meetings with key partners to promote patients’ perspectives as pharmaceutical solutions for liver diseases are developed.
Hill Day Visits
